TOXICITY ASSESSMENT OF BIOSYNTHESIZED SILVER NANOPARTICLES FROM Solanum villosum Mill. (SOLANACEAE) – In vitro AND in vivo STUDY

ABSTRACTObjective: The aim of the study is evaluation of toxicity assessment of biosynthesized silver nanoparticles from Solanum villosum (Mill.) using in vitro and in vivo study.Materials and Methods: Biologically synthesized silver nanoparticles are characterized by UV, SEM, EDAX, XRD analysis and its cytotoxicity effect against HepG2cell lines was performed. Further toxicity was confirmed by in vivo studies using wistar albino rats. Various hematological, liver function marker enzymes and liver histopathology are investigated.The cytotoxic effect of Solanum villosum silver nanoparticles (SV-AgNPs) was also concentration dependent and did not produce any toxicity to tested animals. The histopathological evidence are supported to biochemical observations.Conclusion: So biologically synthesized silver nanoparticles are toxic only to cancer cells but not in animals were proved by present study. Key Words: SV-AgNPs (Solanum villosum silver nanoparticles), HepG2  cell lines, Scanning electron microscopy (SEM), energy dispersive x-ray spectroscopy (EDAX), X-ray diffraction analysis (XRD).Â

EVALUATION OF FREE RADICAL SCREENING AND ANTIOXIDANT POTENTIAL OF MORINGA CONCANENSIS NIMMO-A MEDICINAL PLANT USED IN INDIAN TRADITIONAL MEDICATION SYSTEM

Objective: We aimed to investigate the free radical scavenging, antioxidant and hepatoprotective potential of M. concanensis Nimmo leaves.Methods: Free radical scavenging activity was evaluated by employing various accepted in vitro­ systems, such as 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), hydroxyl (OH) and nitric oxide (NO) radical. Antioxidant potential of M. concanensis Nimmo extract was assessed against H2O2 in goat liver by determination of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione S-transferase (GST), glucose-6-phosphatase dehydrogenase (G-6-PDH), total reduced glutathione (GSH), vitamin C, vitamin E activity, and lipid peroxidation (LPO).Results: Results showed that the amount of plant extract of M. concanensis Nimmo required to scavenge 50% of the DPPH radicals was 401.80 μg/ml, ABTS radical was 353.14 μg/ml, OH radical was 433.71 μg/ml and NO radical was 371.24 μg/ml. Also, the pre-treatment of ethanolic extract of M. concanensis Nimmo leaves in goat liver showed a significant protection against H2O2 induced oxidative stress by retaining of antioxidants of SOD (4.76±0.25), CAT (26.81±0.25), GPx (6.41±0.34), GST (2.31±0.10), G-6-PDH (0.84±0.02), GSH (37.30±1.12), vitamin C (3.01±0.07), vitamin E (14.43±0.45) within normal range.Conclusion: In conclusion, promising free radical scavenging, the antioxidant activity of M. concanensis Nimmo leaves can be able to treat various diseases caused by free radicals

HIGH-PERFORMANCE THIN-LAYER CHROMATOGRAPHY ANALYSIS AND FREE RADICAL SCAVENGING POTENTIAL OF SOUTH INDIAN ORTHODOX BLACK TEA

Objective: The objective of this study was to evaluate the free radical scavenging potential and high-performance thin-layer chromatography (HPTLC) fingerprinting of the ethanolic extract of south Indian orthodox black tea (OBT).Methods: Phytochemical analysis was carried out using standard methods, and free radical scavenging activity of the extract was determined using 2,2-diphenyl-1-picrylhydrazyl (DPPH), nitric oxide (NO), superoxide anion (SOD), and hydroxyl radical scavenging capacities. The ethanolic extract of OBT was loaded in the pre-coated HPTLC plates (silica gel 60 F 254) E-MERCK KGaA. HPTLC was carried out with toluene: ethyl acetate: diethylamine (7:2:1), chloroform: methanol:formic acid (8.5:1.0:0.5), and butanol: isopropyl alcohol (1:1) as mobile phase for alkaloids, flavonoids, and terpenoids, respectively.Results: HPTLC results confirmed that the extract contained several potential active components such as flavonoids, alkaloids, and terpenoids as the slides revealed multicolored bands of varying intensities. Extract of OBT reliably showed the total phenolics 132.27 mg/g, flavonoids 72.52 mg/g, and alkaloids 66.01 mg/g of dry matter. The IC50 value of OBT for DPPH was found to be 372.22 μg/ml, SOD 311.93 μg/ml, NO 362.17 μg/ml, hydroxyl radical 342.14 μg/ml, and reducing power 178.54 μg/ml.Conclusion: The HPTLC fingerprinting profile developed for ethanolic extract will help in proper identification and quantification of marker compounds. The ethanolic extract of OBT was found to possess a wide range of phytochemicals with excellent antioxidant properties. This information may help to choose the best beverage to be consumed in the future

Factors Associated With the Decay of Anti-SARS-CoV-2 S1 IgG Antibodies Among Recipients of an Adenoviral Vector-Based AZD1222 and a Whole-Virion Inactivated BBV152 Vaccine

BackgroundThe magnitude of protection conferred following recovery from COVID-19 or by vaccine administration, and the duration of protective immunity developed, remains ambiguous. MethodsWe investigated the factors associated with anti-SARS-CoV-2 S1 IgG decay in 519 individuals who recovered from COVID-19 illness or received COVID-19 vaccination with two commercial vaccines, viz., an adenoviral vector-based (AZD1222) and a whole-virion-based inactivated (BBV152) vaccine in Chennai, India from March to December 2021. Blood samples collected during regular follow-up post-infection/-vaccination were examined for anti-SARS-CoV-2 S1 IgG by a commercial automated chemiluminescent immunoassay (CLIA). ResultsAge and underlying comorbidities were the two variables that were independently associated with the development of a breakthrough infection. Individuals who were >60 years of age with underlying comorbid conditions (viz., hypertension, diabetes mellitus and cardiovascular disease) had a ~15 times and ~10 times greater odds for developing a breakthrough infection and hospitalization, respectively. The time elapsed since the first booster dose was associated with attrition in anti-SARS-CoV-2 IgG, where each month passed was associated with an ebb in the anti-SARS-CoV-2 IgG antibody levels by a coefficient of -6 units. ConclusionsOur findings advocate that the elderly with underlying comorbidities be administered with appropriate number of booster doses with AZD1222 and BBV152 against COVID-19

Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants

The rapid spread of SARS-CoV-2 variants in the global population is indicative of the development of selective advantages in emerging virus strains. Here, we performed a case-control investigation of the clinical and demographic characteristics, clinical history, and virological markers to predict disease progression in hospitalized adults for COVID-19 between December 2021 and January 2022 in Chennai, India. COVID-19 diagnosis was made by a commercial TaqPath COVID-19 RT-PCR, and WGS was performed with the Ion Torrent Next Generation Sequencing System. High-quality (&amp;lt;5% of N) complete sequences of 73 Omicron B.1.1.529 variants were randomly selected for phylogenetic analysis. SARS-CoV-2 viral load, number of comorbidities, and severe disease presentation were independently associated with a shorter time-to-death. Strikingly, this was observed among individuals infected with Omicron BA.2 but not among those with the BA.1.1.529, BA.1.1, or the Delta B.1.617.2 variants. Phylogenetic analysis revealed severe cases predominantly clustering under the BA.2 lineage. Sequence analyses showed 30 mutation sites in BA.1.1.529 and 33 in BA.1.1. The mutations unique to BA.2 were T19I, L24S, P25del, P26del, A27S, V213G, T376A, D405N and R408S. Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and the Omicron BA.1.1.529 variant but not with Omicron BA.1.1 or BA.2 suggests that the newer strains are largely immune escape variants. The number of vaccine doses received was independently associated with increased odds of developing asymptomatic disease or recovery. We propose that the novel mutations reported herein could likely bear a significant impact on the clinical characteristics, disease progression, and epidemiological aspects of COVID-19. Surging rates of mutations and the emergence of eclectic variants of SARS-CoV-2 appear to impact disease dynamics.Funding Agencies|Xiamen University Malaysia Research Funding (XMUMRF) [XMUMRF/2018-C2/ILAB/0001, XMUMRF/2020-C5/ITCM/0003, XMUMRF/2018-C1/IENG/0005]; Swedish Research Council; Swedish, Physicians against AIDS Research Foundation; Swedish International Development Cooperation Agency; SIDA SARC; VINNMER for Vinnova; Swedish Society of Medicine [AI52731]; Department of Science and Technology-Science and Engineering Research Board, Government of India [CRG/2019/006096]; CALF; Linkoeping University Hospital Research Fund</p

Table_2_Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants.pdf

The rapid spread of SARS-CoV-2 variants in the global population is indicative of the development of selective advantages in emerging virus strains. Here, we performed a case-control investigation of the clinical and demographic characteristics, clinical history, and virological markers to predict disease progression in hospitalized adults for COVID-19 between December 2021 and January 2022 in Chennai, India. COVID-19 diagnosis was made by a commercial TaqPath COVID-19 RT-PCR, and WGS was performed with the Ion Torrent Next Generation Sequencing System. High-quality (<5% of N) complete sequences of 73 Omicron B.1.1.529 variants were randomly selected for phylogenetic analysis. SARS-CoV-2 viral load, number of comorbidities, and severe disease presentation were independently associated with a shorter time-to-death. Strikingly, this was observed among individuals infected with Omicron BA.2 but not among those with the BA.1.1.529, BA.1.1, or the Delta B.1.617.2 variants. Phylogenetic analysis revealed severe cases predominantly clustering under the BA.2 lineage. Sequence analyses showed 30 mutation sites in BA.1.1.529 and 33 in BA.1.1. The mutations unique to BA.2 were T19I, L24S, P25del, P26del, A27S, V213G, T376A, D405N and R408S. Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and the Omicron BA.1.1.529 variant but not with Omicron BA.1.1 or BA.2 suggests that the newer strains are largely immune escape variants. The number of vaccine doses received was independently associated with increased odds of developing asymptomatic disease or recovery. We propose that the novel mutations reported herein could likely bear a significant impact on the clinical characteristics, disease progression, and epidemiological aspects of COVID-19. Surging rates of mutations and the emergence of eclectic variants of SARS-CoV-2 appear to impact disease dynamics.</p

Table_1_Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants.pdf

The rapid spread of SARS-CoV-2 variants in the global population is indicative of the development of selective advantages in emerging virus strains. Here, we performed a case-control investigation of the clinical and demographic characteristics, clinical history, and virological markers to predict disease progression in hospitalized adults for COVID-19 between December 2021 and January 2022 in Chennai, India. COVID-19 diagnosis was made by a commercial TaqPath COVID-19 RT-PCR, and WGS was performed with the Ion Torrent Next Generation Sequencing System. High-quality (<5% of N) complete sequences of 73 Omicron B.1.1.529 variants were randomly selected for phylogenetic analysis. SARS-CoV-2 viral load, number of comorbidities, and severe disease presentation were independently associated with a shorter time-to-death. Strikingly, this was observed among individuals infected with Omicron BA.2 but not among those with the BA.1.1.529, BA.1.1, or the Delta B.1.617.2 variants. Phylogenetic analysis revealed severe cases predominantly clustering under the BA.2 lineage. Sequence analyses showed 30 mutation sites in BA.1.1.529 and 33 in BA.1.1. The mutations unique to BA.2 were T19I, L24S, P25del, P26del, A27S, V213G, T376A, D405N and R408S. Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and the Omicron BA.1.1.529 variant but not with Omicron BA.1.1 or BA.2 suggests that the newer strains are largely immune escape variants. The number of vaccine doses received was independently associated with increased odds of developing asymptomatic disease or recovery. We propose that the novel mutations reported herein could likely bear a significant impact on the clinical characteristics, disease progression, and epidemiological aspects of COVID-19. Surging rates of mutations and the emergence of eclectic variants of SARS-CoV-2 appear to impact disease dynamics.</p